Innovation Pharmaceuticals Inc (IPIX)

[CallMeCrazy]

I agree with you. Here's why.

According to Future Medicine, annual costs associated with treating all types of mucositis in approximately 522,000 patients annually total $13.23 billion.

Galera has managed to raise over $250 million in the last six years, including $150 million in equity and royalty deals ($80 million which was based on future sales of CG4419) about three months ago. Galera has rallied plenty of support from venture capital, with financing partners including Clarus Ventures, Adage Capital Management, Novartis Venture Fund and more.


In the Galera trial, treatment with GC4419 in the higher cisplatin group reduced the relative incidence of SOM by 41% compared to placebo in the Intent-to-Treat (ITT) population. In the ITT – IMRT (intensity-modulated radiation therapy) population, the relative incidence of SOM decreased by 39% versus placebo.

In the IPIX trial, treatment with Brilacidin in the modified Intent-to-Treat (mITT) population reduced the relative incidence of SOM by 65.0% compared to placebo. In the Per Protocol population, the relative incidence of SOM decreased by 80.3% compared to placebo

An oral therapy can be a double-edged sword. One, it can have a competitive edge as oral drugs are the preferred method of administration for patients compared to laying there while the drug slowly drips through an IV. To that point, an oral drug is far more convenient, with administration available in an array of settings compared to IV. It also less expensive, likely making it the preferred method of not only insurance companies, but also doctors writing the prescriptions.

https://www.baystreet.ca/stockstowatch/5021/A-Look-at-New-Oral-Mucositis-Drugs-Galera-Therapeutics-Capital-Raise-Points-to-Innovation-Pharmaceuticals-Being-Grossly-Undervalued

It appears that B-OM is much more effective than GC4419 and B-OM's method of delivery is preferred by patients, doctors, and insurance companies in a market valued in the billion$ with no FDA approved drug. I consider this sufficient motivation for some investors in GC4419 to engage in nefarious acts aimed at eliminating an obviously, superior competitor.

Message in reply to:

What everyone is missing is the real connecting of the dots. It’s quite unfortunate IPIX is on the OTC. It has given a private company the ability to try and destroy their competitor with means of OTC tricks and some proxies. Do some DD, do some tech savvy snoops and you’ll be able to see why the negative interest exists here and why the “non shareholders” know so much about the science of two drugs looking for the same wide open market. It’s pretty simple.